Study Reveals Variability in GLP-1 Medications' Effects on Metabolic Health
GLP-1 medications have gained significant attention in the realm of metabolic health due to their ability to regulate appetite, enhance blood sugar control, and facilitate substantial weight loss. A new review analyzing data from 19 clinical trials involving 13,117 adults with overweight or obesity has revealed that different GLP-1 medications can yield distinct effects on cardiometabolic health markers such as blood pressure, cholesterol levels, and blood sugar control.
The researchers developed a scoring tool known as the Cardiometabolic Efficacy Index (CEI) to assess the efficacy of various GLP-1 treatments across seven health markers: body weight, waist circumference, blood sugar, systolic blood pressure, triglycerides, HDL cholesterol, and LDL cholesterol. Scores closer to 1 indicate stronger overall benefits. The findings indicated that higher-dose GLP-1s consistently provided the most significant improvements, with injectable semaglutide at the highest dose achieving the top CEI score, followed by orforglipron and a lower-dose semaglutide.
All three medications resulted in average weight reductions of at least 10%. Notably, the review also highlighted that oral GLP-1 medications performed comparably to injectables. For instance, among adults without type 2 diabetes, orforglipron 36 mg demonstrated a cardiometabolic profile similar to that of oral semaglutide 25 mg.
The study underscores a clear dose-response relationship, where higher doses of GLP-1 medications consistently yield broader health benefits. While weight loss has traditionally been the primary measure of GLP-1 effectiveness, this research contributes to a growing body of evidence suggesting that these medications can address multiple health outcomes. Individuals focused on blood sugar control may benefit from different options than those primarily concerned with LDL cholesterol or blood pressure.
Genetic factors may also influence how individuals respond to these medications, reinforcing the importance of personalized treatment approaches. Therefore, consulting with a knowledgeable healthcare professional is essential for determining the most suitable GLP-1 option based on a comprehensive assessment of health metrics, including blood pressure, cholesterol, and blood sugar levels, alongside weight goals.
It is important to note that the CEI scores reflect how medications compare across various cardiometabolic risk factors, rather than indicating their effectiveness in preventing heart attacks or kidney disease. This scoring system serves as a valuable tool for comparing treatment options without providing a definitive conclusion about their overall health impacts.




